GSK returns rights to Sosei candidate after R&D rethink

27 November 2023

Following a shake-up on the R&D side, British pharma company GSK (LSE: GSK) has opted to stop development of GSK4381406, a GPR35 agonist.

Full rights to the experimental drug will be returned to partner Sosei Heptares (TYO: 4565), the discoverer of the compound, which is thought by scientists to have potential in indications such as irritable bowel disease (IBD).

Sosei and GSK agreed in 2020 to work together on small molecules of this type, taking aim at IBD and other gastrointestinal immune disorders.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK